今天3分钟我们来聊聊60年前两个孩子用命换来的教训——今天RSV疫苗敢走鼻腔这条路

每年冬季，RSV病毒威胁全球儿童健康，曾因疫苗研发失误致2名幼儿死亡，让该领域停滞半个世纪。如今智飞生物鼻喷RSV疫苗获临床试验受理，采用黑猩猩腺病毒载体技术，直击病毒入侵路径，有望为婴幼儿筑起防护盾。 参考文献： 智飞生物. 关于鼻喷重组呼吸道合胞病毒疫苗临床试验申请获得受理的公告. 2026-08-10. 受理号CXSL2600844. Polack FP et al. Fatal enhanced respiratory syncytial virus disease in toddlers. Science Translational Medicine. PMC10712289. https://pmc.ncbi.nlm.nih.gov/articles/PMC10712289/ Huang L et al. Protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing RSV prefusion F glycoprotein in BALB/c mice. Frontiers in Microbiology. 2022. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1041338/full Dicks MDJ et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence. PLoS ONE. 2012. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040385 WHO. Respiratory syncytial virus (RSV) disease burden data. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/rsv 前往小宇宙评论区与主播互动